iRhythm Technologies
IRTC · NASDAQ · Healthcare
$111.75
+$1.39 (+1.24%) today
Market Cap
$3.68B
24h Volume
$137.0M
P/E Ratio
-18.2
52w High
$189.25
52w Low
$101.79
Est. AI Revenue
45%
7-Day Sparkline (Static)
Company facts
Performance
About iRhythm Technologies
iRhythm Technologies is a digital healthcare company focused on the heart. It makes money from its Zio cardiac monitoring service: patients wear a small patch that records heart rhythms, and iRhythm analyzes the data and reports findings to physicians.
AI is the core of that analysis. Zio AI ECG analysis reads the recordings, deep learning arrhythmia detection identifies irregular rhythms, AI cardiac risk tools assess patients, and the Zio AT monitor extends AI-supported monitoring to patients needing faster notification.
Founded in 2006 and headquartered in San Francisco, iRhythm trades on the NASDAQ and employs about 2,400 people.
iRhythm Technologies in the AI buildout
iRhythm sits in the AI Healthcare layer of the AI buildout. Deep learning is central to how the Zio service works: analyzing long stretches of ECG data at a scale human readers could not match, which underpins both its diagnostic accuracy and its cost economics. That makes AI essential to the product rather than decorative. Demand, though, comes from cardiac care volumes and physician adoption, not AI infrastructure spending, so its exposure is applied AI in medicine.
IRTC is tracked in AI Healthcare, rated Growing on the AI Exposure leaderboard.
By the numbers
52-week range
IRTC trades at $111.75, 11% of the way up its 52-week range of $101.79 to $189.25.
Market cap
Market capitalization is $3.68B, with an AI Exposure Score of 45 out of 100.
Next earnings
iRhythm Technologies is next expected to report earnings on November 5, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does iRhythm Technologies do?
iRhythm sells the Zio cardiac monitoring service. Patients wear a patch that records heart rhythms, and iRhythm's deep learning analysis detects arrhythmias and reports findings to physicians.
How is iRhythm exposed to AI?
Deeply at the product level. Deep learning ECG analysis is core to how Zio diagnoses arrhythmias at scale and to its economics. Supercycle rates it an AI Exposure Score of 45 out of 100.
What are iRhythm's main AI products?
Zio AI ECG analysis, deep learning arrhythmia detection, AI cardiac risk assessment, and the Zio AT monitor for patients who need more timely notification of heart rhythm events.
What sector and categories is IRTC in?
iRhythm is in the Healthcare sector. On Supercycle it is categorized under AI Healthcare, reflecting the deep learning at the center of its cardiac monitoring service.
Where is iRhythm based and who leads it?
iRhythm is headquartered in San Francisco, California, and is led by CEO Quentin Blackford. The company was founded in 2006 and employs about 2,400 people.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.